Evidence map›Paper›PMID 30666106›Full record

ArticleInternational journal of nanomedicine2019

Nanotubular TiO

Wei-Chang Xu, Xiao Dong, Jing-Li Ding, Ji-Chun Liu, Jian-Jun Xu, Yan-Hua Tang, Ying-Ping Yi, Chao Lu, Wei Yang, Jue-Sheng Yang and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Bio-OssFrontiers in bioengineering and biotechnology · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Wei-Chang XuDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Xiao DongDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Jing-Li DingDepartment of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Ji-Chun LiuDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Jian-Jun XuDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Yan-Hua TangDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Ying-Ping YiDepartment of Science and Education, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Chao LuDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Wei YangDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Jue-Sheng YangDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Yi GongDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Jian-Liang ZhouDepartment of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China, zhoujianliang2010@163.com.
Nanchang University · CNSecond Affiliated Hospital of Nanchang University · CN

Funding

Development of a preclinical candidate for the treatment of alcoholismR00AA020539 · NIAAA · PURDUE UNIVERSITY · PI VAN RIJN, RICHARD M. · 2013 to 2015
$728k
Development of a preclinical candidate for the treatment of alcoholismK99AA020539 · NIAAA · ERNEST GALLO CLINIC AND RESEARCH CENTER · PI VAN RIJN, RICHARD M. · 2011 to 2012
$178k
NIAAA NIH HHS K99 AA020539NIAAA NIH HHS R00 AA020539
6 · The paper itself

Abstract

Background: Macrophages play important roles in the immune response to, and successful implantation of, biomaterials. Titanium nanotubes are considered promising heart valve stent materials owing to their effects on modulation of macrophage behavior. However, the effects of nanotube-regulated macrophages on endothelial cells, which are essential for stent endothelialization, are unknown. Therefore, in this study we evaluated the inflammatory responses of endothelial cells to titanium nanotubes prepared at different voltages. Methods and results: In this study we used three different voltages (20, 40, and 60 V) to produce titania nanotubes with three different diameters by anodic oxidation. The state of macrophages on the samples was assessed, and the supernatants were collected as conditioned media (CM) to stimulate human umbilical vein endothelial cells (HUVECs), with pure titanium as a control group. The results indicated that titanium dioxide (TiO Conclusion: Our findings expanded our understanding of the complex influence of nanotubes in implants and the macrophage inflammatory response. Furthermore, CM generated from culture on the TiO

Indexed as

BiomarkersCells, CulturedHumansHuman Umbilical Vein Endothelial CellsMacrophagesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NanotubesNeovascularization, PhysiologicPhosphatidylinositol 3-KinasesPhotosensitizing AgentsProto-Oncogene Proteins c-aktTitaniumVascular Endothelial Growth Factor ABiomarkersMAPK1 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Phosphatidylinositol 3-KinasesPhotosensitizing AgentsProto-Oncogene Proteins c-aktTitaniumtitanium dioxideVascular Endothelial Growth Factor AVEGFA protein, humanaxitinibconditioned mediumendothelial cellsstent implantTiO2 nanotubes

Identifiers

PMID30666106
PMCPMC6330985
OpenAlexW2909794455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.